Purpose:To assess clinical outcomes and toxicities in patients with stage III unresectable non-small cell lung cancer (NSCLC) treated with a moderately escalated hypofractionated radiotherapy delivered with Helical Intensity-ModulatedTechnique in combination with sequential or concurrent chemotherapy. Materials and Methods: Sixty-one consecutive patients considered non-progressive after two cycles of induction chemotherapy were treated with a moderately escalated hypofractionated radiation course of 30 daily fractions of 2.25–2.28 Gy each administered in 6weeks up to a total dose of 67.5–68.4 Gy (range, 64.5–71.3 Gy). Thirty-two received sequential RT after two more cycles (total=4 cycles) of chemotherapy, while 29were treated with concurrent chemo-radiation.The target was considered the gross tumor volume and the clinically proven nodal regions, without elective nodal irradiation. Results:With a median follow up of 27 months (range 6–40), 1-year and 2-year OS rate for all patients was 77 and 53%, respectively, with a median survival duration of 18.6 months in the sequential group and 24.1 months in the concomitant group. No Grade !4 acute and late toxicity was reported. Acute Grade 3 treatment-related pneumonitis was detected in 10% of patients.Two patients, both receiving the concurrent schedule, developed a Grade 3 acute esophagitis.The overall incidence of late Grade 3 lung toxicity was 5%. No patients experienced a Grade 3 late esophageal toxicity. Conclusion: A moderately hypofractionated radiation course delivered with a Helical Intensity-ModulatedTechnique is a feasible treatment option for patients with unresectable locally advanced NSCLC receiving chemotherapy (sequentially or concurrently). Hypofractionated radiotherapy with a dedicated technique allows safely dose escalation, minimizing the effect of tumor repopulation that may occur with prolonged treatment time.

Donato, V., Arcangeli, S., Monaco, A., Caruso, C., Cianciulli, M., Boboc, G., et al. (2016). Moderately escalated hypofractionated (chemo) radiotherapy delivered with helical intensity-modulated technique in stage III unresectable non-small cell lung cancer. In Image-Guided Radiotherapy for Effective Radiotherapy Delivery (pp. 49-54). Frontiers Media S.A..

Moderately escalated hypofractionated (chemo) radiotherapy delivered with helical intensity-modulated technique in stage III unresectable non-small cell lung cancer

Arcangeli, S;
2016

Abstract

Purpose:To assess clinical outcomes and toxicities in patients with stage III unresectable non-small cell lung cancer (NSCLC) treated with a moderately escalated hypofractionated radiotherapy delivered with Helical Intensity-ModulatedTechnique in combination with sequential or concurrent chemotherapy. Materials and Methods: Sixty-one consecutive patients considered non-progressive after two cycles of induction chemotherapy were treated with a moderately escalated hypofractionated radiation course of 30 daily fractions of 2.25–2.28 Gy each administered in 6weeks up to a total dose of 67.5–68.4 Gy (range, 64.5–71.3 Gy). Thirty-two received sequential RT after two more cycles (total=4 cycles) of chemotherapy, while 29were treated with concurrent chemo-radiation.The target was considered the gross tumor volume and the clinically proven nodal regions, without elective nodal irradiation. Results:With a median follow up of 27 months (range 6–40), 1-year and 2-year OS rate for all patients was 77 and 53%, respectively, with a median survival duration of 18.6 months in the sequential group and 24.1 months in the concomitant group. No Grade !4 acute and late toxicity was reported. Acute Grade 3 treatment-related pneumonitis was detected in 10% of patients.Two patients, both receiving the concurrent schedule, developed a Grade 3 acute esophagitis.The overall incidence of late Grade 3 lung toxicity was 5%. No patients experienced a Grade 3 late esophageal toxicity. Conclusion: A moderately hypofractionated radiation course delivered with a Helical Intensity-ModulatedTechnique is a feasible treatment option for patients with unresectable locally advanced NSCLC receiving chemotherapy (sequentially or concurrently). Hypofractionated radiotherapy with a dedicated technique allows safely dose escalation, minimizing the effect of tumor repopulation that may occur with prolonged treatment time.
Capitolo o saggio
Helical Tomotherapy ; Moderate Hypofractionation; Locally Advanced NSCLC
English
Image-Guided Radiotherapy for Effective Radiotherapy Delivery
2016
978-2-88919-849-8
Frontiers Media S.A.
49
54
Donato, V., Arcangeli, S., Monaco, A., Caruso, C., Cianciulli, M., Boboc, G., et al. (2016). Moderately escalated hypofractionated (chemo) radiotherapy delivered with helical intensity-modulated technique in stage III unresectable non-small cell lung cancer. In Image-Guided Radiotherapy for Effective Radiotherapy Delivery (pp. 49-54). Frontiers Media S.A..
reserved
File in questo prodotto:
File Dimensione Formato  
Image-Guided_Radiotherapy_for_Effective_Radiotherapy.pdf

Solo gestori archivio

Dimensione 7.27 MB
Formato Adobe PDF
7.27 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/221720
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
Social impact